The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting
Open accessAbstract
BACKGROUND: Patients with type 2 diabetes are at increased risk of cardiovascular events, and there is an associated economic burden attached to this risk. We conducted a retrospective claims database analysis to evaluate incremental cardiovascular costs in diabetic versus non-diabetic patients hospitalized for a cardiovascular event. METHODS: Patients hospitalized for a cardiovascular event between January 1, 2001 and June 30, 2005 were identified from a large US managed-care population. Diabetic patients were identified by evidence of type 2 diabetes in the 12 months prior to the index hospitalization. Direct medical costs and resource use - including inpatient expenditures (for the index and first recurrent hospitalizations), as well as outpatient, laboratory, and pharmacy expenditures (during the 3-year follow-up period) - were determined for patients with or without diabetes. RESULTS: Of the 29,863 patients identified with a cardiovascular hospitalization, 5,501 patients (18.4%) had a history of diabetes in the pre-index period (mean age, 57.8 years; 42.1% female). The overall mean follow-up period was 22.8 months. The incidence of subsequent cardiovascular events in the first year of follow-up was significantly higher for patients with diabetes compared with non-diabetic patients for all types of cardiovascular events except angina. Compared with non-diabetic patients, patients with diabetes had similar mean direct medical costs per patient for the index cardiovascular hospitalization ($17,435 versus $16,917; P = 0.09), and the first recurrent cardiovascular hospitalization ($18,488 versus $17,481; P = 0.2), yet higher mean total direct medical costs per patient for cardiovascular events during follow-up years (Year 1: $8,805 versus $6,982; Year 2: $13,860 versus $10,056; Year 3: $16,149 versus $12,163; all P < or = 0.0002). The cost difference between diabetic and non-diabetic patients remained significant after adjusting for age, gender and other potential confounders in multivariate regression analysis. The mean (SD) total period of inpatient cardiovascular hospitalization after 3 years of follow-up was 3.3 (12.4) days for patients with diabetes compared with 1.8 (5.8) days for non-diabetic patients (P < 0.0001). CONCLUSION: Diabetic patients hospitalized for a cardiovascular event incur higher costs for cardiovascular care than their non-diabetic counterparts. This analysis of the incremental cardiovascular cost and resource use provides the basis for greater accuracy and precision when modeling the economic value of initiatives aimed at reducing cardiovascular morbidity in patients with diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with T2DM had 10% greater risk of CAD, 53% of MI, 58% of stroke, and 112% increased risk of heart failure.”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Patients with T2DM had 10% greater risk of CAD, 53% of MI, 58% of stroke, and 112% increased risk of heart failure.”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [68]
The cited source says what the claim attributes to it.
In the citing paper
“Patients with T2DM had 10% greater risk of CAD, 53% of MI, 58% of stroke, and 112% increased risk of heart failure.”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [68]
The cited source says what the claim attributes to it.
In the citing paper
“Patients with T2DM had 10% greater risk of CAD, 53% of MI, 58% of stroke, and 112% increased risk of heart failure.”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698 · cited 1×
“Diabetes is a wellestablished risk factor for future cardiovascular events [2], including coronary heart disease (CHD), ischemic stroke, and peripheral vascular disease.”
BackgroundGrundy, S. M., Cleeman, J. I., Bairey Merz, C. N., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.001 · Cited by 1,550
Huxley, R., Barzi, F., & Woodward, M. (2006) · BMJ · doi:10.1136/bmj.38678.389583.7c · Cited by 1,534 · cited 1×
“Indeed, the presence of diabetes can increase the risk of CHD and stroke by as much as 5-fold [3-6], in addition to conferring a worse prognosis for survival from a cardiovascular event [7-10].”
BackgroundEconomic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Cited by
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312
“[68] followed 29,863 patients (5501 with T2DM and 24,362 without T2DM) over a 1-year period.”
BackgroundEconomic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Value in Health · doi:10.1016/j.jval.2017.12.019 · Cited by 305
Gao, D., Ning, N., Wang, C., Wang, Y., Li, Q., Meng, Z., Liu, Y., & Li, Q. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073965 · Cited by 232
“T2DM may cause substantial morbidity and mortality and is associated with enormous economic, health, and societal costs [2,3].”
BackgroundMedical costs associated with type 2 diabetes complications and comorbidities.
Li, R., Bilik, D., Brown, M. B., Zhang, P., Ettner, S. L., Ackermann, R. T., Crosson, J. C., & Herman, W. H. (2013) · PubMed · Cited by 141
Vaidya, V., Gangan, N., & Sheehan, J. (2015) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2015.1024661 · Cited by 125
“Analysis of national administrative claims according to 2006 costs showed the direct medical costs to be US$26,035 for MI, 11,178 for heart failure, 7038 for angina and 11,802 for stroke in patients with T2DM [27].”
Background
Metadata
- Authors
- Straka, R. J., Liu, L. Z., Girase, P. S., DeLorenzo, A., & Chapman, R. H.
- Affiliations
- University of Minnesota (US)
- Pfizer (United States) (US)
- Columbia University (US)
- IQVIA (United States) (US)
- Corresponding author
- Straka, Robert J
- Venue
- Cardiovascular Diabetology
- Published
- 2009
- Volume
- 8
- Issue
- 1
- Pages
- 53
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC2762466
- OpenAlex
- W2060220120
- Cited by
- 67
- References
- 25
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 15 · 2023: 7 · 2022: 4 · 2021: 1 · 2020: 2 · 2018: 5 · 2017: 5 · 2016: 5 · 2015: 9 · 2014: 2 · 2013: 2 · 2012: 2
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- type 2 diabetes, cardiovascular events, cardiovascular hospitalization, health care costs, resource utilization (health care), recurrent hospitalization, economic burden of diabetes, managed care, length of hospital stay, cardiovascular risk in diabetes, angina pectoris, myocardial infarction, stroke, congestive heart failure, heart failure readmission
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Health Resources, Humans, Male, Managed Care Programs, Middle Aged, Retrospective Studies, United States, Cohort Studies, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. https://app.cochat.ai/papers/10.1186/1475-2840-8-53
- The paper
- Straka, R. J., Liu, L. Z., Girase, P. S., DeLorenzo, A., & Chapman, R. H. (2009). Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. Cardiovascular Diabetology. https://doi.org/10.1186/1475-2840-8-53
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.